დასაწყისი · კატალოგი · პროფილი · ცხრილი
სკრინინგი BODY HANDBOOK
სკრინინგი · §91
Adult Cancer Screening Schedule
A small set of screening tests — done on schedule — prevents more cancer deaths per hour of patient effort than almost anything else in adult medicine. The current US Preventive Services Task Force schedule covers five cancers (breast, cervix, colon, lung, skin), and four of them have decades of large trials behind them; the fifth is widely practiced but unsettled. What follows is the schedule itself, what each test actually catches, and where the real decisions are — start ages, intervals, and which test to pick.
Do · Yearly Evidence Strong თავი სკრინინგი

The longevity payoff is large per hour spent — this sits near the top of preventive medicine's leverage list. The schedule is free for almost every insured American and the effort is minor: a handful of appointments a year, with the colonoscopy prep day being the worst single piece. The catch worth knowing: false positives and overdiagnosis are real, and the right decisions on start age, which test to use, and whether to bother with skin exams are genuinely contested at the edges.

Screening works two ways depending on the cancer. For cervical and colon cancer, the test finds and removes precancerous tissue — abnormal cells on the cervix, polyps in the colon — so the cancer never forms. Cervical screening has cut cervical cancer incidence by 60–70% in screened populations Ronco 2014; the longest colonoscopy cohort study showed a 68% drop in colorectal cancer death among people who had one Nishihara 2013.

For breast and lung cancer, the test doesn't prevent the cancer — it finds it small, before it has spread, when surgery alone can usually cure it. The big lung trial that established CT screening (the NLST) showed a 20% drop in lung cancer deaths and a 6.7% drop in all deaths over about six years NLST 2011. Mammography catches breast cancers at lower stage and smaller size; the mortality reduction across the trials is roughly 15–30% Tabár 2011.

Skin sits in a third category. A clinician (or you) looks at the skin for lesions that look different from the rest — asymmetric, irregular border, multiple colors, growing. Whether routine visual exams in healthy adults actually save lives has not been settled by a randomized trial, and the USPSTF has held an insufficient-evidence position on it since 2009 USPSTF 2023.

The schedule

For average-risk adults with no family history or strong risk factors, the current USPSTF schedule:

One pack-year is a pack a day for a year. Twenty pack-years is a pack a day for 20 years, or two packs a day for 10. Most current and former heavy smokers qualify; most don't know they do, and only about 6% of eligible Americans actually get the scan Wolf 2024.

None of this is the whole picture if you have a family history. A first-degree relative diagnosed with colon cancer at 45 shifts your colonoscopy start to 35. A BRCA1 or BRCA2 mutation puts breast screening on MRI plus mammogram in your late twenties. The risk-adjusted schedule lives further down the article.

Why this is the schedule

Cancer screening has more big-trial evidence behind it than almost any other preventive medicine. Each piece of the schedule above is built on data the rest of the catalogue rarely sees.

For breast cancer, eight randomized trials run from the 1960s to the 1990s plus a Swedish cohort followed for 29 years converge on a 15–30% reduction in breast cancer death in women invited to screen Marmot 2013Tabár 2011. For colon cancer, the Minnesota stool-blood trial showed a 33% reduction in colon-cancer mortality with annual at-home testing over 13 years Mandel 1993.

For cervical cancer, four European randomized trials of HPV-based screening showed a 60–70% reduction in invasive cervical cancer compared to Pap-only screening Ronco 2014. US cervical cancer mortality has fallen from about 14 per 100,000 in the 1950s to 2.2 per 100,000 today — almost entirely because of Pap and HPV screening Siegel 2024.

Skin is the outlier. A German mass-screening project saw a 48% drop in melanoma deaths after one round, but it was an observational study and the effect didn't hold up at longer follow-up Katalinic 2012. The USPSTF concluded in 2023 — for the third time — that there's still not enough evidence to recommend routine skin exams in healthy adults USPSTF 2023.

How the schedule changes with risk

The default schedule assumes you're average risk. Several things move the start date earlier, the interval shorter, or both.

  • Family history of colon cancer. A first-degree relative (parent, sibling, child) diagnosed before 60 means colonoscopy starts 10 years before the relative's age at diagnosis — or at 40, whichever is earlier — and repeats every five years instead of ten Smith ACS 2020.
  • BRCA1 or BRCA2 mutation, or a strong family history of breast cancer. Annual MRI plus annual mammogram starting at 25–30. Risk-reducing surgery is a separate, bigger conversation.
  • Lynch syndrome. Colonoscopy every one to two years from age 20–25, lifelong. Plus screening for endometrial, gastric, and urinary cancers.
  • Dense breast tissue. The imaging center now has to tell you (most US states require it). Supplemental ultrasound or MRI is often offered through insurance; the USPSTF says the evidence for it isn't fully there yet, but most dense-breast patients get the extra scan anyway USPSTF 2024.
  • Heavy smoker who doesn't quite fit the USPSTF lung window. The American Cancer Society in 2023 dropped the 15-year quit-window requirement; some pulmonologists will screen you regardless Wolf 2024.
  • Many atypical moles, prior melanoma, organ transplant, or very fair skin with heavy sun history. Dermatology will set you up on a personalized full-body-exam interval — usually every six to twelve months — even though the USPSTF hasn't endorsed it for the general population.

Two notes on sex. Cervical screening applies to anyone with a cervix, including trans men who haven't had a hysterectomy. Mammography is for women; male breast cancer is rare enough that the USPSTF doesn't screen for it unless there's a BRCA mutation in the family. Trans women on long-term feminizing hormones don't have a USPSTF recommendation; specialty consensus is to start mammography after five or more years of hormone therapy, at age 50 or older.

Cost, time, and how it fits into a normal life

For insured Americans, the Affordable Care Act mandates zero cost-sharing on every USPSTF Grade A or B preventive service at the recommended interval — meaning the screening itself is free at the door. The follow-up workup after a positive screen (a diagnostic mammogram, a biopsy, a second colonoscopy after a positive stool test) sometimes hits a copay or deductible depending on the plan. Uninsured adults can use the CDC's free breast-and-cervical screening program for income-eligible women, plus state-level colon screening programs.

Time commitments per round, in normal-life units: a mammogram is 20 to 30 minutes plus travel; a Pap smear is 5 to 10 minutes tacked onto a routine visit; the at-home stool test is 5 minutes and a stamp; a colonoscopy is 90 minutes plus a day of clear-liquid prep and a half-day of recovery; a low-dose lung CT is 10 minutes plus the drive; a full-body skin exam is 10 minutes at a clinic. The annual aggregate, for an adult on the full average-risk schedule, is a couple of hours.

The week of any given screen carries a small but real emotional rhythm — a low background hum of dread beforehand, the relief of a clean result, or the cortisol spike of a callback. Being current on the schedule is also a quiet kind of agency: you're not waiting for symptoms to find out. Neither effect is large day to day; both are real, and worth knowing about going in.

What most people get wrong

  • "Earlier detection is always better." Sometimes; sometimes not. Some screen-detected cancers — mostly slow-growing breast tumors and small lung nodules — would never have caused symptoms or shortened life. The patient still gets surgery, radiation, sometimes chemotherapy. The current estimate is that 19–30% of mammography-detected breast cancers are overdiagnosed Welch 2016; NLST overdiagnosed about 18% of the lung cancers it caught Aberle 2013. Screening still saves more lives than it overtreats, but the overtreatment is real.
  • "More frequent is better." Mostly false. Annual mammograms roughly double the false-positive rate over a decade compared to every two years, without a clear mortality difference for average-risk women. Cervical screening every year — the old US default — gave way to every three to five years because the extra benefit was tiny and the colposcopy-and-biopsy harm wasn't USPSTF 2018.
  • "At-home stool tests are second-best." Annual at-home stool testing has comparable mortality benefit to colonoscopy in modeling studies Lew 2019. The harder problem isn't the test, it's doing it every year for thirty years. The right colon test is the one you'll actually do on schedule.
  • "A clean screen means I don't have cancer." It means the test didn't find one. Interval cancers — ones that grow fast enough to appear between screens — happen in every program. A new breast lump, blood in stool, blood in your cough, or a mole that's changing all get worked up regardless of when your last screen was.
  • "The annual full-body skin exam is well-evidenced." It isn't. The USPSTF has held an insufficient-evidence position on routine skin screening since 2009 and reaffirmed it in 2023 USPSTF 2023. Dermatologists routinely do them and many patients find them useful; the trial data hasn't caught up.
  • "All the cancer organizations agree." They don't. The American College of Radiology recommends annual mammography from 40; the American Cancer Society says annual from 45, then biennial from 55; the USPSTF since 2024 says biennial from 40 Monticciolo 2023Oeffinger 2015. ACS in 2023 dropped the quit-window for lung CT; the USPSTF kept it Wolf 2024. The disagreements are at the edges, and they're real.

Where screening falls apart in practice

  • You don't do it on schedule. Single-round screening of any modality helps a little. The mortality benefit comes from sustained on-schedule participation over decades. National US numbers: about 70% up to date for breast, 75% for cervical, 70% for colon, and just 6% of eligible adults for lung Smith ACS 2020Wolf 2024.
  • Nobody asks the family history question carefully. A first-degree relative with colon cancer at 45 shifts your start age from 45 to 35. A grandmother and an aunt with breast cancer shifts the genetic-testing conversation forward by a decade. Most primary care visits don't dig beyond a checkbox.
  • You qualify for lung screening and don't know it. Pack-year math is unfamiliar territory. A pack a day from 25 to 45 is twenty pack-years, and at 50 you qualify even if you quit five years ago. About 14 million Americans fit the criteria; the vast majority haven't been screened Wolf 2024.
  • The false-positive cascade. About 10% of mammograms get called back for additional imaging. Roughly 3% of lung CTs lead to biopsy. Colonoscopy has a complication rate around 2%, with serious bleeding or perforation around 0.05% USPSTF 2021. None of this is enough to make screening net-negative on average, but the harm path is real and worth knowing about going in.
  • You keep screening past the stopping age. Mammography in your 80s and colonoscopy after 75 usually aren't recommended for average-risk people — the lead time to mortality benefit is five to ten years, and a screen-detected cancer in someone with limited life expectancy mostly leads to treatment without a survival gain.

When to skip or stop

What an unscreened decade actually looks like

Anchor on a 55-year-old. The base-rate lifetime cancer-death risks from these five sites, with no screening, run roughly: 2.5% for breast (women), 1.8% for colon, 6.5% for lung in heavy smokers (0.5% in never-smokers), 0.3% for melanoma, 0.2% for cervical (women) Siegel 2024. Small per year, large over a lifetime.

The felt version of those numbers: something like a 1 in 30 to 1 in 50 chance, across the next decade, of presenting with a symptomatic cancer that the schedule would have caught earlier. Symptomatic colon cancer is fatigue and weight loss and blood you notice in the toilet bowl — usually Stage II or III by the time someone images, treatable but with months of surgery and chemotherapy. Symptomatic lung cancer is a cough that doesn't clear up, with 5-year survival below 20% once it's Stage IV. Symptomatic breast cancer is a lump that someone — you, a partner, a GP at a physical — feels, almost always more than a centimeter across by then.

People around you start telling these stories in their late fifties and sixties. The colleague who put off the colonoscopy and got diagnosed at Stage III. The aunt whose lump was a year of dismissed back-pain before someone scanned her. The schedule is the version of you that doesn't end up in those stories — not certainly (interval cancers still happen) but at materially better odds.

What changes if you follow the schedule

Day to day, almost nothing. The aggregate effect over a lifetime is large but invisible — the polyp removed at colonoscopy at 50 was the colon cancer you didn't get at 62; the small abnormality found on mammogram at 53 was the chemotherapy you didn't need at 58. You can't perceive the alternate timeline you avoided.

Week of any given screen: an hour at the imaging center or 90 minutes at the GI lab, the brief uncertainty of waiting for the result, the relief or the callback. Year by year: one or two appointments. Decade by decade: an absolute reduction in lifetime cancer-death risk of roughly half a percentage point to one percentage point across the five sites — modest in absolute numbers, but among the highest-leverage moves in adult preventive medicine in life-years saved per hour spent Lin 2021.

The partner-noticing effect is mostly negative space: you keep being alive and asymptomatic into your seventies while the schedule does its job, and nobody around you registers what didn't happen. The visible payoff is the call from your gastroenterologist three days after the colonoscopy — "we found and removed two polyps, see you in five years" — five extra years of certainty for ninety minutes of inconvenience and a day of clear-liquid prep.

Related

HPV vaccination prevents most cervical cancer cases upstream of any screening test — a Swedish cohort of 1.7 million women showed an 88% reduction in invasive cervical cancer in those vaccinated before age 17 Lei 2020. Prostate cancer screening (PSA testing) is a separate conversation with a USPSTF Grade C in men 55–69, meaning it's an individual shared-decision call rather than a default Johansson 2020. Genetic testing for BRCA1, BRCA2, Lynch syndrome, and other heritable cancer mutations is the upstream conversation that rewrites the schedule for the people who carry them. UV-protection behavior (sunscreen, hats, shade in the middle of the day) is the better-evidenced cousin of skin screening: the USPSTF gives behavioral counseling for fair-skinned people through age 24 a B grade Henrikson 2018. Multi-cancer early-detection blood tests — the single-blood-draw screens now marketed as a way to catch dozens of cancers at once — are the tempting new option, but none has yet matched the trial evidence behind the five screens here; treat them as a possible add-on, not a substitute, and get the proven ones done first.

Related in the handbook
Alternatives
  • — Before paying for a multi-cancer blood test, make sure the proven screens on this schedule are actually done — they save lives the blood test hasn't yet shown it does.
Related
  • — The cancer screens drop neatly into a once-a-year cadence of preventive visits.
  • — Colorectal cancer is one of the cancers this schedule tells you when to screen for.
  • — For long-term smokers, add the annual lung scan to the standard cancer-screening line-up.
  • — PSA is the asterisk on the cancer-screening lineup: discuss it first, since the harms are real.
  • — Beyond the five cancers, the aortic-aneurysm ultrasound is another high-value age-based screen for older men.
  • — Vaccines and cancer screens are the two pillars of grown-up prevention — and HPV shots prevent cancer outright.
  • — Several cancers on this schedule are alcohol-driven; cutting back lowers the risk these tests are hunting for.
  • — Breast screening is one of the cancers on the combined schedule.
  • — Cervical cancer is one of the cancers this schedule tells you when to screen for.
  • — The HPV catch-up shot prevents several of the cancers this schedule screens for, so it's worth doing alongside the checks.
  • — Skin cancer is the DIY entry on the cancer-screening list: five minutes a month at the mirror.
·
91